Bilal Ahmed Siddiqui, Sreyashi Basu, Sonali Jindal, Miao Zhang, Keyi Zhu, Patricia Troncoso, Sabina Sandigursky, Elizabeth Miller, Dimitris Skokos, Achim Moesta, Marissa Mezzancello, Frank A. Seebach, Israel Lowy, Rebecca Slack Tidwell, Padmanee Sharma, Sumit Kumar Subudhi. "Hypervigilance: A phase Ib clinical trial to optimize risk-benefit of nezastomig (PSMAxCD28 costimulatory bispecific antibody) plus cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer (mCRPC).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.7_suppl.tps295